Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $842.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 29.29% to $842.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, down 24.15% year-over-year, with the annual reading at $842.1 million for FY2025, 29.29% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $842.1 million at Intellia Therapeutics, down from $925.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q4 2022, with the low at $672.2 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity surged 191.12% in 2021, then fell 29.29% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then grew by 17.43% to $1.5 billion in 2022, then decreased by 14.42% to $1.3 billion in 2023, then fell by 8.45% to $1.2 billion in 2024, then dropped by 29.29% to $842.1 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $842.1 million, $925.3 million, and $898.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.